Zydelig (Idelalisib) Patent Expiration, LOE Window & CMS Spending

Zydelig (Idelalisib) by Gilead Sciences: FDA Orange Book core substance LOE 2033-09-02, 0 AB generics, $4.6M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN205858 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-09-02
Last Listed Patent or Exclusivity Date2033-09-02
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$4.6M
2024 Medicare Part D Spend$4.4M
2024 Medicaid Spend$234K
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 17.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.